Hemosilate, 125MG/ML , 20 ml

Target species: Cattle, sheep, goats, pigs, horses, dogs and cats.

Indications for use, specifying the target species: Prevention and treatment of surgical, post-traumatic, obstetric and gynecological bleeding.

Pharmacodynamic properties:

Etamylsylate is a haemostatic and angioprotective drug that stimulates platelet adhesion, shortening bleeding time and rapidly and ultimately normalising altered vascular fragility and permeability.
Its mechanism of action is attributed to the inhibition of prostacyclin (PGI2) synthesis which causes platelet disaggregation, vasodilation and increased capillary permeability and the activation of P-selectin, which facilitates the interaction between platelets, leukocytes and endothelium.
It acts on primary haemostasis without affecting prothrombin time, fibrinolysis or platelet count.
In animal models of capillary bleeding, administration of etamsylate shortens bleeding time and hemorrhage severity by up to 50%, reaching maximum effect between 30 minutes and 4 hours after administration.